Gbm Protein — Glioblastoma Multiforme is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Glioblastoma Multiforme (GBM) is the most aggressive and common primary brain tumor in adults, classified as World Health Organization (WHO) Grade IV glioma[1]. Despite being a malignancy rather than a neurodegenerative disease, GBM shares several molecular pathways and therapeutic targets with neurodegenerative conditions, making it relevant to neuro-oncology research.
GBM arises from glial cells (astrocytes or oligodendrocyte precursor cells) and is characterized by rapid growth, invasive behavior, and poor prognosis. The median survival with standard treatment (surgery followed by radiotherapy and temozolomide chemotherapy) is approximately 15 months[2].
GBM is characterized by several key genetic alterations:
| Pathway | Alteration | Therapeutic Target |
|---|---|---|
| RTK/PI3K/AKT | EGFR amplification, PTEN loss | EGFR inhibitors, mTOR inhibitors |
| p53 Pathway | TP53 mutations | MDM2 inhibitors (experimental) |
| Rb Pathway | CDKN2A deletion | CDK4/6 inhibitors |
| MAPK Pathway | BRAF mutations | BRAF/MEK inhibitors |
GBM is classified into distinct molecular subtypes based on gene expression profiles:
| Approach | Status | Description |
|---|---|---|
| Tumor Treating Fields | Approved | Electric fields disrupting cell division |
| CAR-T Cell Therapy | Clinical Trials | Engineered T cells targeting tumor antigens |
| Oncolytic Virus Therapy | Clinical Trials | Engineered viruses targeting GBM cells |
| Immunotherapy Checkpoint Inhibitors | Clinical Trials | PD-1/PD-L1 blockade |
| Targeted Therapy | Clinical Trials | EGFRvIII vaccines, kinase inhibitors |
While GBM is not neurodegenerative, several connections exist:
The study of Gbm Protein — Glioblastoma Multiforme has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Louis DN, et al. WHO Classification of Tumors of the Central Nervous System. Acta Neuropathol. 2016;131(6):803-820. PMID:27157931 ↩︎
Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study. Lancet Oncol. 2009;10(5):459-466. PMID:19269895 ↩︎
Furnari FB, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683-2710. PMID:17974913 ↩︎